IgG4-related systemic disease is an autoimmune disease that was first recognized in the pancreas but also affects other organs. This disease may manifest as tubulointerstitial nephritis (IgG4-TIN), but its clinicopathologic features in the kidney are not well described. Of the 35 patients with IgG4-TIN whose renal tissue specimens we examined, 27 (77%) had acute or progressive chronic renal failure, 29 (83%) had involvement of other organ systems, and 18 of 23 (78%) had radiographic abnormalities. Elevated total IgG or IgG4 serum levels were present in 79%. All pathologic specimens featured plasma cell-rich TIN, with most showing diffuse, expansile interstitial fibrosis. Immune complexes along the tubular basement membranes were present in 25 of 30 (83%). All specimens had a moderate to marked increase in IgG4ϩ plasma cells by immunohistochemistry. We used a control group of 175 pathologic specimens with plasma cell-rich interstitial infiltrates that can mimic IgG4-TIN to examine the diagnostic utility of IgG4 immunostaining. Excluding pauci-immune necrotizing and crescentic glomerulonephritis, IgG4 immunohistochemistry had a sensitivity of 100% (95% CI 90 -100%) and a specificity of 92% (95% CI 86 -95%) for IgG4-TIN. Of the 19 patients with renal failure for whom treatment and follow-up data were available, 17 (89%) responded to prednisone. In summary, because no single test definitively diagnoses IgG4-related systemic disease, we rely on a combination of histologic, immunophenotypic, clinical, radiographic, and laboratory features. When the disease manifests in the kidney, our data support diagnostic criteria that can distinguish IgG4-TIN from other types of TIN.
IgG4-related systemic disease (IgG4-RSD) has been recognized in the past several years as a systemic autoimmune disease, first recognized in the pancreas as sclerosing or autoimmune pancreatitis (AIP). 1, 2 Now, some form of IgG4-RSD disease has been described in nearly every organ system, including the kidney, liver, gallbladder, other gastrointestinal sites, salivary and lacrimal glands, lung, orbit, breast, retroperitoneum, aorta, lymph nodes, skin, pituitary gland, and prostate. [1] [2] [3] [4] [5] [6] [7] The first description of AIP is attributed to Sarles et al. , who speculated on an autoimmune cause due to the presence of significant hypergammaglobulinemia in some patients and absence of evidence of infection. 8 Hamano et al. recognized the connection of elevated serum IgG4 to AIP 9 and documented the presence of IgG4-positive plasma cells in affected patients, both in the pancreas and at extrapancreatic sites. 10 Others have delineated the systemic nature of this condition. 1, 7, 11 Renal disease has been associated with IgG4-RSD, usually in the form of plasma cell-rich tubulointerstitial nephritis (TIN). [12] [13] [14] IgG4-TIN can be mass forming, similar to IgG4-related inflammatory lesions in other organs. 12 Indeed, 30% of patients with AIP show evidence of renal parenchymal involvement by TIN based on the distinctive radiographic appearance. 15 Other renal manifestations of IgG4-RSD include membranous glomerulonephritis (MGN) and hydronephrosis associated with IgG4-related retroperitoneal fibrosis. 10, 14 Groups at Mayo Clinic and in Japan and Korea have proposed diagnostic criteria for IgG4-RSD when it affects the pancreas as AIP. 16, 17 The diagnosis of AIP is based on a combination of serologic (increased IgG and/or IgG4 levels), radiographic (e.g., diffusely enlarged pancreas and pancreatic masses), and histopathologic findings (periductal lymphoplasmacytic infiltrate, storiform fibrosis, and increased IgG4ϩ plasma cells), presence of other organ involvement, and a positive response to steroid therapy. Diagnostic criteria have not been proposed for distinguishing IgG4-related TIN from other types of TIN. In this study of 35 patients with IgG4-TIN, we examined the histopathologic, immunophenotypic, and ultrastructural features, radiographic and serologic findings, and clinical outcomes, including response to therapy. We compared our findings to the immunophenotypic characteristics of a control group of 175 patients with plasma cell-rich interstitial infiltrates due to causes other than IgG4-RSD. Using these data, we propose diagnostic criteria for IgG4-TIN.
RESULTS

Clinical Features of IgG4-TIN
The average age of the 35 patients was 65 years (range, 20 to 81); 30 (86%) were men. Twenty-seven of 35 patients (77%) had acute or progressive chronic renal failure at the time of renal biopsy. The mean serum creatinine (SCr) in all patients with measurements (n ϭ 33) was 3.6 mg/dl (range, 0.9 to 9). Two biopsies were done for nephrotic-range proteinuria; these biopsies showed MGN in addition to TIN, and these patients did not have distinct renal mass lesions radiographically. Three patients underwent nephrectomy or partial nephrectomy. Nine patients (26%) had renal mass lesion(s) found radiographically as the primary indication for biopsy or nephrectomy; 3 of these patients also had chronic renal failure. The mean SCr in patients with specimens for mass lesions was 1.4 mg/dl, whereas it was 4.2 mg/dl in patients with biopsies for renal failure.
Other Organ Involvement
Twenty-nine of 35 patients (83%) had known current or previous clinical, radiographic, and/or histologic evidence of other organ involvement by a systemic inflammatory disease. Most patients with extrarenal involvement had multiorgan involvement. Table  1 lists the sites affected. Of note, no patient showed only lymphadenopathy, cutaneous vasculitis, thyroiditis, or arthritis.
Radiographic Features of IgG4-TIN
In patients with available radiographic data, 18 of 23 (78%) showed radiographic abnormalities. These abnormalities consisted of small low-attenuation lesions, usually bilateral and multiple, or a mass in 14 patients or bilateral markedly enlarged kidneys (Ն14.5 cm) in 4 patients. (See Table 1 .)
Laboratory Features of IgG4-TIN Overall, 22 of 25 patients (88%) had increased serum total IgG or IgG4 levels or hypergammaglobulinemia. Fifteen of 19 patients (79%) with measurements available had elevated serum total IgG and/or IgG4 levels, with 11 of 15 (73%) with known elevated IgG levels and 11 of 12 (92%) with known elevated IgG4 levels. Six of 18 patients (33%) had peripheral blood eosinophilia. Fourteen of 25 patients (56%) had hypocomplementemia, with decreased serum C3 (11 of 26, 42%) and/or C4 levels (12 of 26, 46%). Ten of 32 patients (31%) had a positive ANA, all but 1 of which were weakly or transiently positive. No patients had current positive tests for hepatitis B or C infection. Two patients had positive antimyeloperoxidase antibodies, but without evidence of a necrotizing or crescentic glomerulonephritis on biopsy. Eight of 27 patients with urine data had Ͼ1 g/d proteinuria (range, 0 to 16 g/d), and 6 patients had hematuria. Two patients (both with MGN) had nephrotic-range proteinuria.
Histologic and Immunophenotypic Features of IgG4-Related TIN
By light microscopy (LM), all pathologic specimens by definition showed a diffuse or multifocal TIN with increased plasma cells, as well as mononuclear cells. All but four specimens showed numerous eosinophils that were sometimes prominent. Focal mild mononuclear cell tubulitis was seen in most cases; plasma cell tubulitis was seen rarely. 30 of 35 cases had an expansile interstitial fibroinflammatory process, whereas 5 of 35 cases showed an acute interstitial nephritis pattern with only minimal interstitial fibrosis (Ͻ10% of cortex) and without an expansile interstitial process (pattern A). The ratio of fibrosis to inflammation showed variability from specimen to specimen; some (24 of 35) had a more densely cellular inflammatory lesion with expansile interstitial fibrosis present (pattern B), whereas others (6 of 35) had collagen-rich, paucicellular fibrosis (pattern C). Some specimens showed variability of degrees of fibrosis and inflammation within each tissue sample. Thirty of 35 specimens (86%) showed moderate to severe interstitial fibrosis and tubular atrophy in the biopsy or within areas of the inflammatory mass on nephrectomy samples. In some areas of tubular atrophy, only fragments of residual TBMs could be seen. Three patients with nephrectomy samples showed normal renal parenchyma outside of the inflammatory mass lesion. Two nephrectomy samples revealed a more fibrotic and less inflammatory region at the center of the mass, with a more inflammatory, less fibrotic pattern at the periphery.
No vascular fibrinoid necrosis was identified in any specimen. Glomeruli appeared normal or showed mild mesangial matrix expansion. Three specimens had immunofluorescence (IF) evidence of glomerular immune complex deposits: one showed granular mesangial IgG, C3, and kappa and lambda light chains (patient 35), and two showed MGN with granular glomerular capillary loop IgG, C3, and kappa and lambda light chains (patients 29 and 30).
All 34 IgG4-TIN specimens with sufficient material for immunohistochemistry (IHC) showed moderate to marked increase in IgG4ϩ plasma cells. Thirteen of 34 showed a moderate increase in IgG4ϩ cells and 21 of 34 showed a marked increase.
Overall, 25 of 30 specimens (83%) with immunostaining or electron microscopy (EM) performed showed TBM immune complex deposits by IHC for IgG4, IF (22 of 26, 85%), and/or EM (11 of 16, 69%). By IF, all specimens with deposits showed granular TBM staining for IgG. Those specimens with IgG and staining information for other immunoreactants also showed accompanying kappa and lambda light chains, and often accompanying C3 of lesser staining intensity. Three specimens showed TBM granular staining for C1q, two of which also showed TBM IgM, and one other specimen showed IgM without C1q. The TBM deposits were diffuse in 14 patients and focal in 9 patients with data available. By EM the TBM deposits were amorphous and electron dense. (See Figure 1. ) TBM deposits were present in areas with interstitial inflammation by EM, and not present in the normal areas of one nephrectomy examined.
TBM deposits were more commonly found in specimens with patterns B (20 of 21, 95%) and C (5 of 6, 83%) than in those with pattern A (0 of 3, 0%). This difference was statistically significant for pattern A versus pattern B (P ϭ 0.002) and pattern A versus pattern C (P ϭ 0.048). There was no significant difference in prevalence of positive ANA, hypocomplementemia, elevated serum IgG or IgG4, or presence of other organ involvement in the patients with TBM deposits versus those without.
Control TIN Specimens for IgG4 Staining
Control pathologic specimens were obtained by two methods: (1) by biopsy review of all native renal biopsies during a given year (2007) with significant interstitial inflammation and (2) by diagnosis on specimens outside of the given year that could mimic IgG4-TIN clinically, radiographically, and/or histologically and that showed interstitial inflammation.
Within the given year (2007), 414 renal biopsies were identified with moderate or severe interstitial inflammation according to the pathology report, including 167 patients with associated nondiabetic glomerular disease; within this time period, 4492 native kidney biopsies were examined at our institution. Of the biopsies with interstitial inflammation, 82 of 414 (20%) had increased plasma cells, defined for screening purposes as Ͼ5 plasma cells/ϫ400 magnification (hpf) in Ն3 fields, with etiology as follows: 20 (24%) drug effect, 18 (22%) unknown cause, 15 (18%) associated with pauci-immune necrotizing and crescentic glomerulonephritis (GN), 14 (17%) associated with other glomerular disease (immune-mediated crescentic GN, focal segmental glomerulosclerosis, and diabetes), 9 (11%) autoimmune disease, 2 (2%) pyelonephritis, 2 (2%) confirmed or possible IgG4-TIN, 1 (1%) antiglomerular basement membrane (GBM) nephritis, and 1 (1%) oxalate nephropathy.
Fourteen of 82 biopsies (17%) from the control interstitial inflammation group showed moderate or marked increase in IgG4ϩ plasma cells, defined as 11 to 30 cells per hpf (moderate) and Ͼ30 cells per hpf (marked). These biopsies with increased IgG4ϩ plasma cells were pauci-immune GN (n ϭ 6 of 15 total biopsies stained), TIN due to drug (2 of 20), autoimmune TIN (2 of 9, including 1 of 2 with lupus glomerulonephritis), chronic pyelonephritis (1 of 2), unknown cause (1 of 18), and possible or confirmed IgG4-TIN (2 of 2). Two of these biopsies showed TBM deposits by IF, one with IgG4-TIN and the other with an autoimmune TIN possibly representing lupus interstitial nephritis. None of the other biopsies with TIN with increased IgG4ϩ plasma cells showed TBM deposits. Stained biopsies from the control time period with no increase in IgG4ϩ plasma cells were anti-GBM nephritis (0 of 1) and oxalate nephropathy (0 of 1).
An additional 93 biopsies from outside the given year and chosen by diagnosis were stained for IgG4. Specimens with at least moderately increased IgG4ϩ plasma cells were as follows: 7 of 26 pauci-immune GN, 0 of 19 TIN in patients with a history of acute or chronic pancreatitis (nonautoimmune), 1 of 14 TIN associated with Sjögren syndrome, 2 of 10 pyelonephritis, 1 of 6 unknown cause, 1 of 8 proliferative lupus nephritis with TBM immune deposits, along with 0 of 5 other autoimmune (including 2 biopsies with hypocomplementemic TIN with TBM deposits) and 0 of 5 drug reaction. One of 6 pauci-immune GN showed a focal marked increase in IgG4ϩ plasma cells, whereas other controls stained showed only a focal moderate increase.
In total, excluding IgG4-RSD and pauci-immune GN, 11 of 131 TIN biopsies (8.4%) studied showed at least a moderate increase in IgG4ϩ plasma cells. If pauci-immune GN is excluded, the IgG4 stain has a sensitivity of 100% (confidence interval [CI] 0.90 to 1) and a specificity of 92% (CI 0.86 to 0.95) for TIN as part of IgG4-RSD. Table 2 .) Twenty-one patients, 19 of whom had renal insufficiency at biopsy, were treated with prednisone; two patients received mycophenolate mofetil in addition to prednisone. Two patients required dialysis. Seventeen of 19 patients with renal insufficiency showed a decrease in SCr with treatment that included steroids. The mean pretreatment (including one patient treated with surgery only) SCr was 3.5 mg/dl (range, 1.1 to 8.5), and posttreatment was 1.7 mg/dl (range, 1.0 to 3.3, excluding one patient with endstage renal disease). Two patients showed no improvement CLINICAL RESEARCH www.jasn.org Table 1 . Hyper-gammaglobulinemia CLINICAL RESEARCH www.jasn.org with steroids at 1-and 6-month follow-up: one patient remained on dialysis and developed end-stage renal disease despite steroid treatment, and another patient died with chronic renal failure 11 months after the biopsy. Two patients showed a response to steroid therapy but experienced a relapse with increased SCr upon steroid taper. Two patients with normal renal function were also treated with prednisone and showed continued normal SCr at 1.1 and 1 mg/dl on follow-up. One patient (patient 20) was treated with nephrectomy only and showed decreased SCr on follow-up from 1.4 to 1.0 mg/dl at 84-months postnephrectomy. Five patients were not treated medically or surgically and showed increased or continued el- evated SCr (average 2.2 mg/dl, range 1.2 to 4.4) from 1 to 64 months after diagnosis (average 26 months). There was no correlation between histologic pattern and response to therapy, and even patients with extensive fibrosis on biopsy showed response to steroid treatment.
DISCUSSION
TIN is a disease pattern with heterogeneous causes, both immune and nonimmune. The clinical presentation, laboratory results, and biopsy features are all considered to make a specific diagnosis. Some systemic autoimmune diseases, such as sarcoidosis, Sjögren syndrome, systemic lupus erythematosus, and IgG4-RSD, may include autoimmune TIN as a manifestation of disease. Occasionally, the systemic disease is unrecognized at the time of renal biopsy. In these patients, the recognition of an autoimmune etiology for TIN aids in diagnosis of that particular systemic disease and can guide therapy.
In this series, we describe the clinical and pathologic features in 35 kidney specimens, including 30 patients not previously described. In most of these patients, TIN as part of IgG4-RSD shows some unusual features not typically encountered in other forms of TIN: in particular, TBM immune complex deposits, a moderate to marked increase in IgG4-positive plasma cells, elevated serum total IgG and/or IgG4 levels or hypergammaglobulinemia, and peculiar radiographic findings (low-attenuation renal lesions, often multiple and bilateral, or diffuse marked enlargement of kidneys). A combination of these features, in conjunction with clinical history suggestive of a systemic inflammatory disease, allows one to make a diagnosis of IgG4-TIN.
We examined the utility of the IgG4 stain in distinguishing IgG4-TIN from other forms of TIN with increased plasma cells. In the pancreas, increased IgG4ϩ plasma cells distinguish inflammatory infiltrates of AIP from those associated with other conditions. 18 We surveyed an unbiased series of TIN biopsy patients from 1 year for increased plasma cells; an additional comparison group of specific types of plasma cell-rich infiltrates in the clinicopathologic differential diagnosis of IgG4-TIN was also included. One pitfall of IgG4 staining was that approximately 32% of pauci-immune GN tissue specimens showed at least moderately increased IgG4ϩ plasma cells. With the exclusion of pauci-immune GN tissue specimens, IgG4 staining in this series showed a high sensitivity and specificity for IgG4-TIN; additional clinical, radiographic, and laboratory features can contribute to increased certainty of the diagnosis, if these features are not suggestive of another cause of TIN. One common feature in IgG4-TIN was TBM immune complex deposits. TBM deposits are unusual in TIN outside of interstitial inflammation associated with proliferative lupus nephritis and a subset of Sjögren syndrome patients, and were rarely present in our other control TIN tissue specimens. TBM deposits were more likely to be present in patients with expansile fibrosis (patterns B and C) than in those with an acute interstitial nephritis pattern (A), and TBM deposits were not found in areas away from those involved by interstitial inflammation. The TBM deposits thus may correlate with disease progression, although whether these deposits are causative of tubular injury or a result of inflammatory injury remains to be seen.
In this series of IgG4-TIN, 88% of patients showed elevated serum total IgG, IgG4, or hypergammaglobulinemia, including 79% with a known increase in serum IgG or IgG4. Similar findings have been reported in several studies of AIP in which 70 to 80% of patients show increased serum IgG or IgG4. 19 Hamano et al. showed that the largest fraction of hypergammaglobulinemia in AIP was composed of IgG4, 9 and so the presence of hypergammaglobulinemia in a patient with increased IgG4ϩ plasma cells on kidney biopsy may warrant further serologic testing for IgG and IgG4 levels. Eosinophilia was seen in 33% of our IgG4-TIN patients, and has been observed in AIP. 20 Eosinophilia may also be seen in acute allergic tubulointerstitial nephritis and thus may not be contributory without other clinical or radiographic features. Although these laboratory features can be helpful in making the diagnosis, their absence does not exclude the diagnosis of IgG4-TIN.
In some patients, IgG4-TIN may affect only the kidney at the time of renal biopsy. In the current series, six patients (17%) with IgG4-TIN had no other known organ involvement besides the kidney, although by definition for our series these patients had radiographic and/or laboratory features suggestive of IgG4 disease. It is conceivable that some patients may present with renal involvement of IgG4-RSD, with other clinical features becoming apparent later, or that some patients may have renal involvement only. An additional four biopsies not included in the IgG4-TIN group came from patients with no known other organ involvement, but had a histologic appearance unique to fibrotic IgG4-TIN. Given the histologic and immunophenotypic characteristics being similar to those with other organ involvement, these patients may represent sole renal involvement by IgG4 disease.
One entity in the differential diagnosis of IgG4-related TIN is so-called "idiopathic hypocomplementemic tubulointerstitial nephritis with extensive tubulointerstitial deposits". A total of 12 patients of this hypocomplementemic TIN entity have been described in the literature. [21] [22] [23] Many of these patients likely represent IgG4-TIN, as it was previously not widely recognized. Indeed, many of the described patients were elderly males. Two patients in the largest series of 8 biopsies had a history of sclerosing cholangitis, and one had leukocytoclastic vasculitis on skin biopsy, and so these three patients may represent IgG4-RSD or an overlap syndrome.
Also in the differential diagnosis of IgG4-TIN are Sjögren syndrome and lupus nephritis, both of which are systemic autoimmune diseases that may show interstitial inflammation and tubular basement membrane immune deposits on kidney biopsy. Similar to hypocomplementemic TIN, some patients diagnosed clinically as Sjögren syndrome may represent IgG4-RSD in the form of chronic sclerosing sialadenitis, which shows increased IgG4ϩ plasma cells. 24 Only 1 of 15 patients of Sjögren TIN in our control group showed increased IgG4ϩ plasma cells. Two of 10 lupus nephritis patients in our control group showed increased IgG4ϩ plasma cells. Lupus nephritis patients with TBM deposits can be distinguished histologically from IgG4-TIN by the usual presence of an accompanying proliferative immune complex GN. The presence of an additional glomerular disease or autoimmune condition, however, does not necessarily exclude the diagnosis of a concurrent IgG4-TIN. We observed a range of histologic appearances of IgG4-TIN. One may speculate that these differences are related to the age of the lesion andrepresentdifferentstagesofdisease:(A)acuteinterstitialnephritis with minimal fibrosis; (B) a more cellular inflammatory pattern in the setting of expansile fibrosis; and (C) a very fibrotic, pauci-cellular pattern. Two nephrectomy specimens, which allowed for examination of entire cross sections of mass lesions, showed denser fibrosis with less inflammation near the center of the mass and more inflammation resembling acute interstitial nephritis at the periphery, with the central fibrotic area representing the most long-lived area of an expanding mass lesion. Furthermore, the biopsy that showed the most severe fibrotic changes came from a patient with longstanding AIP, although the duration of renal involvement was unknown.
The standard medical therapy for AIP with pancreatic involvement is glucocorticoids. Patients typically show a marked response to prednisone or prednisolone, but there is a high relapse rate. 25 Less is known about the response to treatment in IgG4-related TIN. Saeki et al. showed a decrease in SCr at one month follow-up in most patients treated with prednisolone who had an elevated SCr at presentation. 13 We found a similar response rate to prednisone, sometimes combined with mycophenolate, in patients who had elevated SCr before treatment. Of note, even patients with markedly increased SCr and patients with diffuse interstitial fibrosis on biopsy showed a response to therapy, which may reflect steroid responsiveness of these fibrotic lesions, or perhaps the patchy nature of inflammatory lesions. Similar response rates have been published in the pancreatic literature in which a response to steroid treatment is typically seen within 2 weeks. 25 On the basis of this study, we propose diagnostic criteria for IgG4-TIN, based on histologic and immunophenotypic features, imaging, laboratory results, and other organ involvement. In addition to typical histology with a plasma cell-rich infiltrate (often with expansile interstitial fibrosis) and increased IgG4ϩ plasma cells, patients must have features from at least one other category including imaging (low-attenuation renal lesions or marked enlargement of kidneys), serology (elevated IgG or IgG4 levels), and other organ involvement by an inflammatory process. (See Table 3 .) Pancreatic diagnostic criteria include response to steroids as a diagnostic criterion. Renal involvement differs from pancreatic involvement in IgG4-RSD, as many patients present with renal failure rather than, or in addition to, amasslesion.AlthoughIgG4-TINrespondsintermsofSCrtosteroid therapy, so do other types of TIN, and so steroid responsiveness is not deemed a diagnostic feature of IgG4-RSD in the kidney. Response to steroids of mass lesions in the kidney or in other organs, however, may help confirm the diagnosis.
In summary, IgG4-RSD is a distinct clinical entity with various patterns of organ involvement. As no single serologic or other test yet exists to diagnose this disease definitively, we rely on a combination of histologic, immunophenotypic, clinical, radiographic, and laboratory features to make the diagnosis. When this disease manifests in the kidney as TIN, the proposed criteria can distinguish IgG4-TIN from other types of TIN.
CONCISE METHODS
This study was approved by the Institutional Review Boards at Mayo Clinic and Massachusetts General Hospital; pathologic specimens originating at other institutions were reviewed at Mayo Clinic.
IgG4-TIN Patients
Patients were identified from Mayo Clinic, Nephropathology Associates, MA General Hospital, and Louisiana State University Health Sciences Center who had renal tissue findings of TIN and clinical, serologic, or radiographic features suspicious for IgG4-TIN (n ϭ 35, including 5 patients previously reported 12 ). To qualify as "suspicious" for IgG4-TIN, renal specimens must have shown a plasma cell-rich TIN and at least one of the following criteria: (1) Clinical evidence of other organ involvement by IgG4-RSD, (2) laboratory results of increased serum total IgG or IgG4 levels or hypergammaglobulinemia, or (3) radiographic features in the kidney of small peripheral cortical nodules, round or wedge-shaped lesions, or diffuse patchy involvement by computed tomography scan or magnetic resonance imaging as described in AIP, 15 or marked diffuse enlargement of kidneys by ultrasound.
Four additional specimens of TIN were identified that showed similar expansile plasma cell-rich TIN to patients with IgG4-RSD but did not qualify by our definition of suspicious for IgG4-TIN due to absence of data regarding other clinical, laboratory, or radiographic features. All four specimens showed a moderate to marked increased in IgG4ϩ plasma cells by IHC. One of these four specimens also showed concurrent MGN. These four specimens were deemed inconclusive for IgG4-TIN and were excluded from the statistical analyses. Two additional renal tissue specimens were identified from patients with a clinical history of IgG4-RSD; one showed MGN and the other showed renal cell carcinoma. These patients did not show a histologic pattern of TIN and were not included in the study.
Clinical data, presenting clinical, radiographic, and laboratory findings, medical history, treatment, and follow-up were obtained from referral forms submitted at the time of biopsy, patients' medical records, and telephone interviews with the referring physicians. Laboratory results specifically sought were elevated total serum IgG and IgG4 levels (defined as Ͼ1590 mg/dl and Ͼ121 mg/dl, respectively), polyclonal hypergammaglobulinemia (Ͼ1.6 g/dl), peripheral blood eosinophilia (defined as counts Ͼ0.5 ϫ 10 9 per liter or Ͼ5% of peripheral white blood cells), serum C3 and C4 levels, ANCA, MPO, or PR3 antibodies, antinuclear antibody, anti-double-stranded DNA antibody, and studies for hepatitis B and C infection.
Control TIN Specimens
A database search of Mayo Clinic native renal biopsies was performed for all patients within 1 year (2007) with a final diagnosis of TIN, including some biopsies with associated glomerular disease. The cause of TIN in each patient was determined based on clinical and laboratory data. LM slides of all TIN patients were reviewed for increased plasma cells, defined for screening purposes as Ͼ5 cells per ϫ400 magnification (hpf) in Ն3 fields. Those biopsies with increased plasma cells were stained for IgG4 by IHC (see below). Specific subtypes of TIN on biopsies done outside of the given year were also included: acute and/or chronic TIN in patients with a history of pancreatitis, pauci-immune GN, TIN in patients with Sjögren syndrome, proliferative lupus nephritis with interstitial inflammation and TBM deposits, drug-related TIN with increased plasma cells, chronic pyelonephritis, and unknown or possible autoimmune TIN with increased plasma cells. The Fisher exact test was used for statistical correlations; a P value of Ͻ0.05 was considered statistically significant; 95% confidence intervals were calculated for sensitivity and specificity using the Wilson score method without continuity correction.
Light Microscopy, Immunofluorescence, and Electron Microscopy
Standard processing for renal biopsies not performed for suspicion of tumor consisted of LM, IF, and EM. For LM, samples were stained with hematoxylin and eosin (H&E), periodic acid-Schiff, Masson's trichrome, and Jones methenamine silver. For IF, 3-m cryostat sections were stained with polyclonal FITC conjugated antibodies to IgG, IgM, IgA, C3, C1q, kappa, lambda, fibrinogen, and albumin (Dako Corp., Carpinteria, CA). Biopsies and nephrectomies performed for suspicion of tumor were routinely stained for H&E only. In IgG4-TIN specimens without material originally submitted for EM, EM was performed on deparaffinized tissue obtained from the light microscopy blocks, if sufficient tissue and blocks were available. LM slides were reviewed and IF and EM reports were reviewed on control biopsies; EM images were also reviewed in tissue specimens of IgG4-TIN.
Light microscopy slides were reviewed on all tissue specimens by a central pathologist (LDC). The interstitial nephritis was classified by the predominant pattern on the specimen as (A) acute interstitial nephritis with minimal fibrosis (Ͻ10% of cortex), (B) a more cellular inflammatory pattern in the setting of expansile fibrosis, and (C) a very fibrotic, pauci-cellular pattern. The degree of interstitial fibrosis and tubular atrophy was defined as mild (Յ25%), moderate (26 to 50%), or severe (Ͼ50%).
IgG4 Immunohistochemistry and IgG4 Grading
IHC was performed using the avidin-biotin complex-peroxidase method with monoclonal antibody to human IgG4 (Zymed, Carlsbad, CA; dilution 1:50 or 1:100 depending on staining laboratory) on sections from paraffin-embedded tissue. IgG4-positive plasma cells were counted per ϫ400 magnification (hpf) and graded in the most densely concentrated area as follows: no increase Ͻ5 cells per hpf, mild increase 5 to 10 cells per hpf, moderate increase 11 to 30 cells per hpf, and marked increase Ͼ30 cells per hpf. IgG4 staining was performed on control TIN specimens with increased plasma cells and in TIN specimens in patients with clinical, serologic, or radiographic features suspicious for IgG4-TIN/IgG4-RSD.
